Erythropoietin in cardiorenal anemia syndrome

Incidents of heart and renal failure (HF, RF) together, are increasing in our country and all over the world, so a great attention has been dedicated to this problem recently. These diseases together have shown bad results because of the process of accelerated arteriosclerosis, structural changes of...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules & biomedicine 2006-11, Vol.6 (4), p.36-41
Main Authors: Fazlibegović, Emir, Hadziomerović, Mustafa, Corić, Slavica, Babić, Emil, Fazlibegović, Fadila
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anemia - drug therapy
Blood Glucose - metabolism
Blood Urea Nitrogen
cardio-renal anemia syndrome
Creatinine - blood
Cytokinins - blood
Cytokinins - physiology
Epoetinum beta
Erythrocyte Count
erythropoietin
Erythropoietin - therapeutic use
Female
Heart Diseases - blood
Heart Diseases - drug therapy
heart failure
Hematopoiesis - physiology
Hemoglobins - metabolism
Humans
Inflammation - pathology
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - drug therapy
Male
Malnutrition - complications
Middle Aged
Potassium - blood
Recombinant Proteins
Renal Dialysis
renal failure
Syndrome
Tumor Necrosis Factor-alpha - metabolism
Tumor Necrosis Factor-alpha - physiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Incidents of heart and renal failure (HF, RF) together, are increasing in our country and all over the world, so a great attention has been dedicated to this problem recently. These diseases together have shown bad results because of the process of accelerated arteriosclerosis, structural changes of myocardium, oxidative stress, inflammation, increased activities of sympathetic nervous system (SNS), increased activities of a renin-angiotensin-aldosterone system (RAAS) (1). These factors are crucial in the development of patho-physiological process and consequential development of anemia, that together with heart and renal failure through interaction, cause serious disorder that we call the cardio-renal anemia syndrome (2). We examined effects of erythropoietin (Epoetin beta) at 90 (60 men and 30 women) pre-dialysed and dialysed patients with HF signs during a period of three years in individual dozes of 2000-6000 units subcutaneous (sc) weekly. Using computer S PLUS and SAS multiple variant analysis we have got correlations by Pearson. Epoetin beta significantly develops anemia parameters: number of erythrocytes (r=0.51779; p
ISSN:1512-8601
2831-0896
1840-4812
2831-090X
DOI:10.17305/bjbms.2006.3117